We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Hisamitsu Pharmaceutical and Nippon Shinyaku announced on April 7 that they
have entered into a joint development agreement for HFT-290, a drug candidate
for the treatment of cancer pain.
Array BioPharma today announced an expansion of a collaboration agreement with
Genentech to develop small molecule drugs against an additional protein target
in the field of oncology.
Cardinal Health on Friday said it received a subpoena from New York state's
attorney general as part of a broad industry probe into a segment of the drug
wholesaling industry.
Drug developer Regenera will start receiving royalty income from next year after
signing a licensing deal with one of the US's leading ophthalmology companies
that is potentially worth up to $US140 million ($183 million).
Lincolnshire-based Takeda Pharmaceuticals North America
Inc. plans to relocate and expand its headquarters in Deerfield, adding 500
new jobs with help from the state of Illinois.
Maxygen and Roche are completing late-stage preclinical studies and manufacturing
on their collaborative effort to develop improved interferon alpha protein therapeutics
to treat hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, and
they expect to file an investigational new drug application toward Phase I clinical
trials next year, Maxygen said.
Barr Laboratories and Kos Pharmaceuticals have initiated settlement talks to
resolve their outstanding patent litigation regarding Kos' brand drug Niaspan,
the companies announced.
The most reliable method for demonstrating the efficacy of a cancer drug or
biologic is to show a statistically significant improvement in a clinically
meaningful endpoint in blinded, randomized, controlled trials, but there are
single-arm study approaches that might be successful in certain settings, explains
a new FDA draft guidance.
The HHS has awarded a $97 million contract to sanofi pasteur to support the
development of cell culture-based influenza vaccines, an advanced type of flu
vaccine the agency hopes can be manufactured faster and in larger volumes than
traditional egg-based vaccines.